Patient Engagement/Monitoring

Bruno Villetelle Joins Seqster Advisory Board

Bruno Villetelle, Global Head of Data and Digital in Novartis Global Drug Development, joins Seqster as they prepare for unprecedented growth and expansion.

Seqster PDM, Inc. (“Seqster”), the leading patient-centric healthcare technology company, today announced the appointment of Bruno Villetelle, a global pharma, Data and Digital leader to its strategic advisory board.

“Bruno is an innovator in the Life Sciences industry and has successfully led digital transformations for global pharmaceutical companies. We are so honored to have him join our strategic advisory board, especially during this time of rapid growth and development for us,” said Ardy Arianpour, CEO & Co-Founder of Seqster.

The Seqster operating system is the ‘standard of excellence’ for Operating Systems for Decentralized Trials™, Clinical Studies and Digital Health. It aggregates and automates patient data collection for studies, enabling data streams to be analyzed to identify novel biomarkers for Real World Evidence (RWE) and accelerated drug discovery.  The platform also facilitates patient engagement and long-term patient retention in current and future studies.

Mr. Villetelle currently leads Novartis’ Data and Digital in Global Drug Development, and is focused on fully integrating Data science and Digital technology into the drug portfolio and development processes. Prior to joining Novartis, he became the first Chief Digital Officer ever nominated in the pharma industry at Takeda. His impressive track record of leading Fortune 500 enterprises’ Data and Digital strategy and transformation makes him an ideal candidate for the Seqster advisory position.

“Data silos and fragmented health data is indeed one of the most pressing issues in the healthcare ecosystem” said Bruno Villetelle, Head of Data and Digital Global Drug Development at Novartis.  “Successful trials and drug development has never been more critical than it is today. The Seqster operating system, by automating patient data collection, in real-time, and breaking down the health data silos has huge potential to create remarkable value for drug development.  It can change the paradigm of an industry that has had to rely on conventional data collection methods that take long, are costly, and often times, are ineffective. I am thrilled to join Seqster’s board and be part of this industry evolution.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to

Related posts

Metaverse in Healthcare Market worth $71.2 Billion by 2030

Business Wire

agilon health Appoints Two New Executives to Leadership Team

Business Wire

Kareo and PatientPop Named Leaders by Real Users

Business Wire